Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
![]() | 4,7-Dichlorothieno[2,3-d]pyridazine REF: IN-DA005GKYCAS: 699-89-8 | 95% | To inquire | Tue 04 Mar 25 |
![]() | 4,7-Dichlorothieno[2,3-d]pyridazine REF: 10-F079744CAS: 699-89-8 | 95.0% | 34.00 €~480.00 € | Wed 05 Mar 25 |
![]() | 4,7-Dichlorothieno[2,3-d]pyridazine REF: 54-OR905814CAS: 699-89-8 | 95% | 32.00 €~1,335.00 € | Tue 11 Mar 25 |
![]() | 4,7-Dichlorothieno[2,3-d]pyridazine REF: 3D-FD135167CAS: 699-89-8 | Min. 95% | - - - | Discontinued product |
![discount label](https://static.cymitquimica.com/public/img/discount.png)
4,7-Dichlorothieno[2,3-d]pyridazine
CAS:699-89-8
Formula:
C6H2Cl2N2S
Purity:
95%
Color and Shape:
Solid
Molecular weight:
205.0645
Ref: IN-DA005GKY
1g | 118.00 € | ||
5g | 245.00 € | ||
100mg | 38.00 € | ||
250mg | 50.00 € |
Estimated delivery in United States, on Tuesday 4 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
4,7-Dichlorothieno[2,3-d]pyridazine
CAS:699-89-8
Purity:
95.0%
Color and Shape:
Solid, No data available.
Molecular weight:
205.05999755859375
Ref: 10-F079744
1g | 80.00 € | ||
5g | 256.00 € | ||
10g | 480.00 € | ||
250mg | 34.00 € |
Estimated delivery in United States, on Wednesday 5 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
Ref: 54-OR905814
1g | 131.00 € | ||
5g | 561.00 € | ||
25g | 1,335.00 € | ||
100mg | 32.00 € | ||
250mg | 41.00 € |
Estimated delivery in United States, on Tuesday 11 Mar 2025
![discount label](https://static.cymitquimica.com/public/img/discount.png)
4,7-Dichlorothieno[2,3-d]pyridazine
CAS:699-89-8
4,7-Dichlorothieno[2,3-d]pyridazine is a phosphorescent compound with a yellow color. It has an emission peak at …
Formula:
C6H2Cl2N2S
Purity:
Min. 95%
Molecular weight:
205.06 g/mol
Ref: 3D-FD135167
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |